Welcome to our dedicated page for CME GROUP SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CME GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CME GROUP's regulatory disclosures and financial reporting.
CME Group Inc. reported record first-quarter 2026 results, with revenue of $1.88 billion, up 14% from a year earlier. Operating income rose to $1.31 billion, while net income reached $1.15 billion and diluted earnings per share were $3.18.
On a non-GAAP basis, adjusted operating income was $1.37 billion, adjusted net income was $1.22 billion and adjusted diluted EPS were $3.36, each at record levels. Trading activity was exceptionally strong, with average daily volume hitting an all-time high of 36.2 million contracts, up 22%, and non-U.S. volume rising 30%. The company also returned significant capital, paying approximately $2.7 billion in dividends and repurchasing $536 million of shares in the quarter.
CME Group Inc. director William R. Shepard reported buying a net 1,469.84 shares of Class A common stock at $297.38 per share. The purchases on March 26, 2026 included 1,407.78 shares acquired indirectly through a trust and 62.06 shares acquired in his direct account.
The indirectly held shares rose to 260,117.54 held by a trust, while directly held shares increased to 2,539.45. A footnote explains that the acquired shares reflect a dividend reinvestment plan administered by his broker, meaning cash dividends were automatically used to buy additional CME shares.
CME Group Inc - Amendment to Schedule 13G
The Vanguard Group filed Amendment No. 10 reporting 0 shares beneficially owned of CME Group common stock, representing 0% of the class. The amendment explains an internal realignment effective January 12, 2026 leading certain Vanguard subsidiaries or business divisions to report ownership separately in reliance on SEC Release No. 34-39538.
CME Group is asking shareholders to vote at its May 14, 2026 annual meeting on director elections, auditor ratification, executive pay and major charter changes to Class B director election rights. The proxy highlights record 2025 results, including $6.5 billion in revenue, $4.1 billion in net income and diluted EPS of $11.16. Average daily volume reached 28.1 million contracts, with international volume of 8.4 million contracts per day. CME declared more than $4 billion in 2025 dividends, including a $2.2 billion variable dividend, and increased the regular dividend to $5.00 per share annually. The filing also details a heavily independent, skills-diverse board, extensive risk and cybersecurity oversight, and a pay program tying over half of executive compensation to performance.
CME Group Inc. senior managing director and general counsel Jonathan L. Marcus reported an open-market sale of 3,291 shares of Class A common stock on March 17, 2026 at $313.37 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and he now holds 7,192 shares directly. This Form 4/A amendment only corrects the reported sale price; all other details from the original Form 4 remain the same.
CME Group Inc. senior managing director and general counsel Jonathan L. Marcus reported an open-market sale of 3,291 shares of Class A common stock at $333.37 per share. After this transaction, he directly holds 7,192 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 18, 2025, indicating it was scheduled in advance rather than timed discretionarily.
CME Group reported a Form 144 notice for a proposed sale of issuer-held equity. The filing lists 3,291 total shares identified for sale: 398 Restricted Stock and 2,893 Performance Shares, each dated 03/15/2026. The securities are described as ISSUER-held on NASDAQ.
CME Group Inc. senior managing director Timothy Francis McCourt reported equity compensation activity involving Class A common stock. He received a grant or award of 5,504 shares at a reference price of $311.40 per share tied to performance share vesting from a 2022 award. In related non-market transactions, he surrendered 2,810 shares and separately 94 shares back to the company to cover tax withholding obligations on the performance share award and restricted stock vesting. After these transactions, he holds 12,108 shares of CME Group Class A common stock directly.
CME Group Inc. senior managing director and general counsel Jonathan L. Marcus received an equity award of 5,270 shares of Class A common stock on March 15, 2026. The vesting amount was based on CME’s total shareholder return versus the S&P 500 over a three-year period from January 1, 2023 through December 31, 2025.
On the same date, Marcus surrendered 2,377 shares to the company to cover tax withholding on the performance share award and 261 shares to cover taxes on restricted stock vesting. These tax-withholding dispositions were not open-market sales. After these transactions, he directly holds 10,483 CME Class A shares.